- Home
- AIRI vs GTBP Comparison
AIRI vs GTBP Comparison
Compare AIRI & GTBP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | AIRI | GTBP |
|---|---|---|
| Founded | 1979 | 1965 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Military/Government/Technical | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 12.3M | 12.4M |
| IPO Year | 2013 | 2016 |
Fundamental Metrics
Financial Performance| Metric | AIRI | GTBP |
|---|---|---|
| Price | $2.65 | $6.20 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 8.3K | ★ 217.5K |
| Earning Date | 11-13-2026 | 11-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 24.39 | 3.75 |
| EPS | N/A | ★ N/A |
| Revenue | ★ $47,921,000.00 | N/A |
| Revenue This Year | $4.34 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $2.30 | $0.22 |
| 52 Week High | $3.95 | $11.98 |
Technical Indicators
Market Signals| Indicator | AIRI | GTBP |
|---|---|---|
| Relative Strength Index (RSI) | 45.88 | 55.30 |
| Support Level | $2.55 | $0.36 |
| Resistance Level | $2.76 | $11.98 |
| Average True Range (ATR) | 0.08 | 1.03 |
| MACD | -0.01 | -0.34 |
| Stochastic Oscillator | 26.77 | 0.00 |
Price Performance
Historical ComparisonAbout AIRI Air Industries Group
Air Industries Group is an aerospace and defense company. Its manufacturers of precision components and assemblies for large aerospace and defense prime contractors. The company products include landing gears, flight controls, engine mounts and components for aircraft jet engines, ground turbines and other complex machines. The ultimate end-user of products is the U.S. Government, international governments, and commercial global airlines.
About GTBP GT Biopharma Inc.
GT Biopharma Inc is a clinical-stage biopharmaceutical company focused on the development and commercialization of novel immuno-oncology products in the United States. The company is engaged in discovering, developing, and commercializing therapeutics from its proprietary product platform across various disease areas, mainly focused on the treatment of cancer. Its TriKE (Tri-specific Killer Engager) platform offers immuno-oncology products designed to treat hematologic malignancies, sarcoma, and solid tumors.